Advertisement
DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line
(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.
Charles River Research Models & Services (RMS) sales and marketing teams will collaborate with DURECT to jointly market and commercialize the ALZET product line to existing and new customers over a multi-year period.
Charles River RMS will provide dedicated marketing resources and collaborate with DURECT to develop and roll out a broad range of sales and marketing initiatives for ALZET.
DURECT will remain responsible for manufacturing, marketing support, order fulfillment and customer billing.
read more
Charles River Laboratories Slashes FY24 Outlook - Update
While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews
|
455 dias atrás
Charles River Laboratories Reaffirms FY24 Outlook; Q1 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) reaffirmed its adjusted earnings, revenue growth and organic revenue growth guidance range for the full-year 2024.
RTTNews
|
545 dias atrás
Charles River Laboratories Narrows FY23 Outlook Range; Q3 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) narrowed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance range for the full-year 2023.
RTTNews
|
728 dias atrás
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.
RTTNews
|
909 dias atrás
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss
While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews
|
1190 dias atrás
DURECT Appoints Timothy Papp As New CFO
Biopharmaceutical company DURECT Corp. (DRRX) announced Tuesday the appointment of Timothy Papp as its Chief Financial Officer. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.
RTTNews
|
1219 dias atrás
Australian Market Halves Its Early Gains In Mid-market
The Australian market is halving its early gains in mid-market moves on Thursday, reversing some of the losses in the previous two sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,800 level, with gains across most sectors led by mining and energy stocks amid rebounding commodity prices.
RTTNews
|
1h 6min atrás
Asian Markets Track Wall Street Higher
Asian markets are trading mostly higher on Thursday, following the broadly positive cues from Wall Street overnight, as some traders looked to pick up stocks at reduced levels following the recent sell-off. Traders also react to upbeat private US economic data and growing expectations that the US Supreme Court may reject the Trump administration's aggressive trade policy.
RTTNews
|
1h 33min atrás
